Patents by Inventor Jennifer Effie AMENGUAL

Jennifer Effie AMENGUAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20230165813
    Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.
    Type: Application
    Filed: August 4, 2022
    Publication date: June 1, 2023
    Inventors: Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL, Donald W. LANDRY, Ottavio ARANCIO, Luigi SCOTTO, Shixian DENG, Rosa PURGATORIO, Jole FIORITO
  • COMBINATION THERAPY OF LYMPHOMA
    Publication number: 20230167451
    Abstract: The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 1, 2023
    Inventors: Jennifer Effie AMENGUAL, Jennifer LUE, Owen A. O'CONNOR
  • Combination therapy of lymphoma
    Patent number: 11597933
    Abstract: The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: March 7, 2023
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jennifer Effie Amengual, Jennifer Lue, Owen A. O'Connor
  • Histone acetyltransferase activators and compositions and uses thereof
    Patent number: 11406608
    Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: August 9, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Owen Anthony O'Connor, Jennifer Effie Amengual, Donald W. Landry, Ottavio Arancio, Luigi Scotto, Shixian Deng, Rosa Purgatorio, Joie Fiorito
  • HISTONE ACETYLTRANSFERASE (HAT) REGULATORS AND USES THEREOF
    Publication number: 20220125748
    Abstract: The invention provides for compounds that are HAT activators or inhibitors. The invention further provides a method for treating neurodegenerative diseases, cancer and other malignant conditions, or to increase memory in a subject not suffering from a neurodegenerative disease by administering HAT activators or inhibitors to a subject in need thereof. The method further comprises co-administration of HD AC inhibitors with HAT activators or HD AC activators with HAT inhibitors.
    Type: Application
    Filed: February 7, 2020
    Publication date: April 28, 2022
    Inventors: Ottavio ARANCIO, Donald W. LANDRY, Shixian DENG, Jennifer Effie AMENGUAL, Elisa ZUCCARELLO, Jole FIORITO, Yuxuan LIU, Elisa CALCAGNO, Luuk Elard DE VRIES
  • Histone acetyltransferase activators and uses thereof
    Patent number: 11191768
    Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: December 7, 2021
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Ottavio Arancio, Shixian Deng, Donald W. Landry, Jole Fiorito, Rosa Purgatorio, Owen Anthony O'Connor, Jennifer Effie Amengual
  • HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20200330410
    Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.
    Type: Application
    Filed: May 8, 2020
    Publication date: October 22, 2020
    Inventors: Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL, Donald W. LANDRY, Ottavio ARANCIO, Luigi SCOTTO, Shixian DENG, Rosa PURGATORIO, Jole FIORITO
  • COMBINATION THERAPY OF LYMPHOMA
    Publication number: 20200263185
    Abstract: The present disclosure provides for methods and compositions for treating cancer. A subject having lymphoma is administered an EZH2 inhibitor and an HDAC inhibitor. The combination of the EZH2 inhibitor and the HDAC inhibitor produces a synergistic effect on the cancer compared to the effect of the EZH2 inhibitor or the HDAC inhibitor alone.
    Type: Application
    Filed: November 29, 2018
    Publication date: August 20, 2020
    Inventors: Jennifer Effie AMENGUAL, Jennifer LUE, Owen A. O'CONNOR
  • Histone acetyltransferase activators and compositions and uses thereof
    Patent number: 10653648
    Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: May 19, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Owen Anthony O'Connor, Jennifer Effie Amengual, Donald W. Landry, Ottavio Arancio, Luigi Scotto, Shixian Deng, Rosa Purgatorio, Jole Fiorito
  • HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF
    Publication number: 20200101078
    Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tan protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 2, 2020
    Inventors: Ottavio ARANCIO, Shixian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL
  • Histone Acetyltransferase Activators and Uses Thereof
    Publication number: 20180360842
    Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
    Type: Application
    Filed: January 11, 2018
    Publication date: December 20, 2018
    Inventors: Ottavio ARANCIO, Shi Xian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL
  • HISTONE ACETYLTRANSFERASE ACTIVATORS AND COMPOSITIONS AND USES THEREOF
    Publication number: 20180021273
    Abstract: The invention provides pharmaceutical compositions and methods for treating cancer, neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein by administering a HAT modulator and a HDAC modulator to a subject.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 25, 2018
    Inventors: Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL, Donald W. LANDRY, Ottavio ARANCIO, Luigi SCOTTO, Shi Xian DENG, Rosa PURGATORIO, Jole FIORITO
  • HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF
    Publication number: 20170182054
    Abstract: The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.
    Type: Application
    Filed: March 30, 2015
    Publication date: June 29, 2017
    Inventors: Ottavio ARANCIO, Shixian DENG, Donald W. LANDRY, Jole FIORITO, Rosa PURGATORIO, Owen Anthony O'CONNOR, Jennifer Effie AMENGUAL